The International Journal of Neuropsychopharmacology
A consensus-based presentation of operational criteria for TRD and PRD, combined with a review of biological mechanisms and trial design innovations, intended to standardize definitions and inform future clinical research rather than report a primary empirical finding.
The International Journal of Neuropsychopharmacology
Large, well-designed cross-sectional neuroimaging and genetic study with unsupervised clustering that identifies distinct MDD subtypes and their cardiometabolic risk profiles, but lacks prospective validation, longitudinal follow-up, and independent replication needed to confirm clinical utility.
The International Journal of Neuropsychopharmacology
A sound cross-sectional study with pre-specified biomarker hypotheses and ROC analysis showing female-specific IL-6 and CRP associations with MDD in obesity, but limited by small sample size, single setting, and lack of longitudinal or independent validation.
The International Journal of Neuropsychopharmacology
Observational cohort analyses from large databases showing associations between modifiable lifestyle factors and brain health outcomes, without randomized comparisons or causal inference; findings are suggestive but require confirmatory intervention trials.
The International Journal of Neuropsychopharmacology
This is a narrative review integrating preclinical mechanisms and early-phase clinical trial data without reporting a primary empirical finding, controlled outcome, or definitive clinical result.
The International Journal of Neuropsychopharmacology
Retrospective analysis of 15 patients treated off-label with esketamine in routine clinical care, without control group, prospective protocol, or quantified outcome measures—early-phase evidence suggesting feasibility and benefit that requires controlled trials for confirmation.
The International Journal of Neuropsychopharmacology
Uncontrolled, preclinical study in a mouse depression model with a mechanistic focus; demonstrates proof-of-concept for ketamine metabolites restoring prosocial behaviors but requires human clinical validation.